ProQR Therapeutics
PRQR
58 hedge funds and large institutions have $28.2M invested in ProQR Therapeutics in 2022 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 18 increasing their positions, 16 reducing their positions, and 33 closing their positions.
2,387% more call options, than puts
Call options by funds: $1.67M | Put options by funds: $67K
13% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 16
22% less funds holding
Funds holding: 74 → 58 (-16)
26.34% less ownership
Funds ownership: 70.95% → 44.61% (-26%)
48% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 33
92% less capital invested
Capital invested by funds: $365M → $28.2M (-$337M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
M28 Capital Management
Stamford,
Connecticut
|
+$3.36M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$3.31M |
| 3 |
Two Sigma Investments
New York
|
+$2.49M |
| 4 |
Renaissance Technologies
New York
|
+$2.02M |
| 5 |
PFM
Privium Fund Management
Amsterdam,
Netherlands
|
+$1.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$16M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$14.9M |
| 3 |
Jennison Associates
New York
|
-$14.5M |
| 4 |
Goldman Sachs
New York
|
-$10.5M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$8.98M |
PRQR Hedge Fund Activity: Q1 2022 in Review
58 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q1 2022, worth a combined $28.2M — down 92% from $365M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of PRQR and 17 opened new positions — a net loss of 16 holders — while 16 trimmed existing stakes and 18 added.
The largest buyer was M28 Capital Management, opening a new position worth an estimated $3.36M. The largest seller was Driehaus Capital Management, exiting entirely with an estimated $16M sold.
- 58 institutional investors held ProQR Therapeutics (PRQR) as of Q1 2022, down from 74 in Q4 2021.
- Funds reported $28.2M of ProQR Therapeutics stock for Q1 2022, down 92% quarter-over-quarter.
- 17 funds opened new ProQR Therapeutics positions in Q1 2022 and 33 closed out, a net change of -16 holders.
- The largest ProQR Therapeutics buyer in Q1 2022 was M28 Capital Management, an estimated $3.36M added.
- The largest ProQR Therapeutics seller in Q1 2022 was Driehaus Capital Management, an estimated $16M sold.
Based on aggregated 13F filings for Q1 2022.